Insider Buying: Shattuck Labs (NASDAQ:STTK) Director Acquires $250,000.00 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) Director Clay Siegall purchased 62,500 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average cost of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director owned 318,608 shares in the company, valued at approximately $1,274,432. This trade represents a 24.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $4.94 on Friday. The firm has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $4.94. Shattuck Labs, Inc. has a one year low of $0.71 and a one year high of $8.33. The company has a market cap of $378.80 million, a price-to-earnings ratio of -7.84 and a beta of 1.08.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter in the prior year, the company earned ($0.27) earnings per share. Equities research analysts expect that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday. Wedbush raised their price objective on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. TD Cowen restated a “buy” rating on shares of Shattuck Labs in a research report on Friday, March 6th. Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price objective on the stock in a research report on Friday, June 5th. Finally, Weiss Ratings cut shares of Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Shattuck Labs in the 3rd quarter worth $38,000. AQR Capital Management LLC raised its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the period. Qube Research & Technologies Ltd purchased a new position in Shattuck Labs in the 2nd quarter worth $44,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs in the 3rd quarter worth $46,000. Finally, Bridgeway Capital Management LLC raised its position in Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after purchasing an additional 55,000 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.